On October 14, 2025, Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced that its HiFi sequencing technology has been chosen as the core platform for the Korea Disease Control and Prevention Agency’s (KDCA) National Pangenome Reference Project. The project, led by the National Institute of Health (KNIH), will sequence more than 1,000 Korean genomes to create the first telomere‑to‑telomere reference set for the population.
The initiative will integrate the resulting data into the global Human Pangenome Reference Consortium (HPRC), providing a comprehensive, high‑accuracy reference that will accelerate discovery of population‑specific variants and support precision diagnostics and therapeutics in Korea.
PacBio will supply an end‑to‑end sequencing solution that spans library preparation, sequencing, and data analysis, leveraging its full HiFi technology suite. CEO Christian Henry said the company is proud that its integrated solutions were selected for this landmark effort, which will serve as a foundation for disease and evolutionary research.
This marks the first national pangenome program to adopt PacBio’s complete technology stack, positioning the company to capture a significant share of the growing global pangenome market and to generate multi‑year revenue from a large, government‑backed project.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.